NEW HAVEN, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company As Precipio continues to expand its product distribution channels (including the latest agreement with ThermoFisher), company management has identified a need for an experienced executive who can manage the process of successfully training hundreds of our channel partners’ sales reps to market HemeScreen.
Ms. Mills’ deep expertise is in high-performing teams and transformational growth; within this role she will be responsible for training our channel distribution partners’ sales teams. This includes creating and maintaining training & educational programs delivered both in person and via the Precipio Academy of Learning (PAL), an online learning portal expected to be live by year end. In addition, she will be creating curricula to support customers and channel partners necessary for achieving Precipio’s growth and revenue goals.
Toni–Ann will be able to leverage the highly experienced sales teams of our distribution partners, ensuring that these teams are well-trained, have a solid technical and business understanding of our products, and their value proposition to the customer, their patients, and the laboratory.
“I have seen firsthand Toni-Ann’s ability to take even the most technical jargon and turn it into an enjoyable development experience. The breadth of experience and expertise she brings to assist the education of customers will be crucial as we expand our team and channel partners supporting the HemeScreen product portfolio,” said Keith Meadors, Precipio’s SVP Products Division. “Toni-Ann’s addition to the team further emphasizes the company’s potential in the Products Division and the importance of bringing in experienced leaders to support the company’s growth potential. I am delighted to have her as part of the team.”
Toni-Ann brings 20+ years of learning and development experience within various large global organizations, including her recent position as Senior Global Director of Commercial Operations, Learning, and Development at Fenwal, within Fresenius Kabi. During her 14-year tenure, Toni-Ann created a global university in-house with complete competency-based sales, clinical education, technical services, and management curricula built around best practices, supporting the MedTech business with revenues of $1.4B annually reported in 2021. Most recently, she was a vital development team member, working with Northwestern University to develop the IMPACT leadership program.
“I’m delighted to become part of the Precipio team. It has been a life-long ambition to work in the field of cancer, and to me, Precipio is a critical player in the pursuit of excellence in helping cancer patients”, said Toni-Ann Mills. “I am excited to be working with this highly experienced and talented team to deliver quality, targeted learning experiences that will enable success for all in being better able to serve Precipio’s channel partners and customers.”
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise, and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics, and treatment, Precipio offers a new standard of diagnostic accuracy, enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated from time to time in the company’s Securities and Exchange Commission filings.
The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.